Adagrasib
Overview
Adagrasib is a small molecule inhibitor targeting the KRAS G12C mutation, a common oncogenic driver in several types of cancer including non-small cell lung cancer (NSCLC). It works by selectively binding to and inhibiting the mutant KRAS protein, thereby inhibiting cancer cell proliferation.
API suppliers (1)
Suppliers of Adagrasib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Adagrasib expires 21 Aug 2043 and exclusivity 12 Dec 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Adagrasib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.